Leigh J. Spera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Leigh J. Spera has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abbas M. Hassan
Indiana University School of Medicine, Indianapolis, USA
2 shared publications - Allison N. Boyd
Department of Pharmacy, Eskenazi Health , Indianapolis, IN 46202
2 shared publications Bacil A Kadi
Purdue University College of Pharmacy, West Lafayette , Indiana , USA
1 shared publication- Brett C Hartman
Richard M. Fairbanks Burn Center, Eskenazi Health, Indianapolis , Indiana , USA
1 shared publication - Deidra B Bedgood
Richard M. Fairbanks Burn Center, Eskenazi Heath , Indianapolis, IN
1 shared publication Elise M Hulsebos
University of Southern California Keck School of Medicine, Los Angeles, California; University of Southern California, Los Angeles, California; University of Southern California, Los Angeles, California; Los Angeles County Department of Health Services, Los Angeles, California; University of Southern California Keck School of Medicine, Los Angeles, California; University of Southern California, L
1 shared publication
Latest Publications
- 18 September 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
Development and Validation of the Skin Graft Loss Risk Estimator: An Interpretable Machine Learning-Driven Tool for Individualized Assessment in Burn Patients
Background: Skin graft failure is a significant complication in burn care that prolongs recovery, compromises surgical outcomes, and necessitates repeat operations. Accurate risk assessment is challenging due to a complex interplay of patient and injury factors, underscoring the need for objective, data-driven predictive tools. We developed and validated an interpretable machine learning (ML)-driven tool to provide individualized, data-driven risk assessment for skin graft loss in patients with burn injuries. Methods: A cohort study of patients who had autologous skin grafting from the American Burn Association Burn Care Quality Platform was conducted from 2013 to 2022. A Random Forest ML model was developed and validated on independent training (70%), validation (15%), and testing (15%) sets. Model performance was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: Of 286 479 patients during the study period, 24 046 underwent autologous skin grafting. Machine learning demonstrated discriminatory predictive performance with AUC-ROC of 0.794. Burns ≥ 40% total body burn surface area (odds ratio [OR] 8.16; P < .001), history of alcohol abuse (OR 1.86; P < .001), active tobacco use (OR 1.45; P = .004), age > 60 years (OR 1.70; P = .013), hypertension (OR 1.52; P = .003), male sex (OR 0.74; P = .009), diabetes mellitus (OR 1.45; P = .030), and contact burns (OR 1.70; P = .006) emerged as independent predictors of graft loss. The model was translated into an interactive, interpretable web-based clinical tool. Conclusions: The Skin Graft Loss Risk Estimator provides a transparent, interpretable and personalized risk assessment of skin graft loss to enhance clinical judgment, facilitate effective patient counseling and surgical planning in burn care.
- 18 September 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
Development and Validation of the Skin Graft Loss Risk Estimator: An Interpretable Machine Learning-Driven Tool for Individualized Assessment in Burn Patients
Background: Skin graft failure is a significant complication in burn care that prolongs recovery, compromises surgical outcomes, and necessitates repeat operations. Accurate risk assessment is challenging due to a complex interplay of patient and injury factors, underscoring the need for objective, data-driven predictive tools. We developed and validated an interpretable machine learning (ML)-driven tool to provide individualized, data-driven risk assessment for skin graft loss in patients with burn injuries. Methods: A cohort study of patients who had autologous skin grafting from the American Burn Association Burn Care Quality Platform was conducted from 2013 to 2022. A Random Forest ML model was developed and validated on independent training (70%), validation (15%), and testing (15%) sets. Model performance was assessed using the area under the receiver operating characteristic curve (AUC-ROC). Results: Of 286 479 patients during the study period, 24 046 underwent autologous skin grafting. Machine learning demonstrated discriminatory predictive performance with AUC-ROC of 0.794. Burns ≥ 40% total body burn surface area (odds ratio [OR] 8.16; P < .001), history of alcohol abuse (OR 1.86; P < .001), active tobacco use (OR 1.45; P = .004), age > 60 years (OR 1.70; P = .013), hypertension (OR 1.52; P = .003), male sex (OR 0.74; P = .009), diabetes mellitus (OR 1.45; P = .030), and contact burns (OR 1.70; P = .006) emerged as independent predictors of graft loss. The model was translated into an interactive, interpretable web-based clinical tool. Conclusions: The Skin Graft Loss Risk Estimator provides a transparent, interpretable and personalized risk assessment of skin graft loss to enhance clinical judgment, facilitate effective patient counseling and surgical planning in burn care.
- 3 March 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 116, 312-314
Development of an open-source, protocol-adherent platform for real-time burn fluid resuscitation management
- 3 March 2026
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 116, 312-314
Development of an open-source, protocol-adherent platform for real-time burn fluid resuscitation management
- 15 January 2025
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
Intrathecal Baclofen Pump Wean and Risk of Exposure in a Large Total Body Surface Area Burn Wound Patient: A Case Report
Burn injuries in patients with significant preexisting medical conditions provide unique challenges in both medical management and surgical planning. Spasticity, if left untreated, can be one of the most disabling consequences of a neurologic injury. Treatment is largely dependent on pharmacologic management with antispasmodic agents such as baclofen. Baclofen’s effectiveness when taken orally is often limited by its systemic side effects, which mostly affect the CNS. Intrathecal baclofen (ITB) can circumvent these intolerable adverse effects while achieving symptom relief via a more targeted therapeutic route. However, abrupt cessation of chronic baclofen use can precipitate an acute life-threatening withdrawal syndrome. We present a case of a 47-year-old female who sustained 54% TBSA full-thickness flame burns to the circumferential bilateral lower extremities, left arm, left anterior and posterior trunk, flank, and perineum. She had a premorbid C5 spinal cord injury resulting in spastic paraplegia for which she had an ITB pump implanted into her left abdominal wall for symptom management. This pump was directly beneath her operative burn wounds. We discuss the complex issues that were encountered throughout her care related to medication reservoir supply, life-threatening risk of baclofen withdrawal, pain-specialist availability, medical-legal barriers, and the multi-staged surgical plan for coverage, balancing proper wound debridement with risk of device exposure and infection. To our knowledge, this is the only case report detailing the cohort of obstacles that may be associated with these devices, specifically with burn patients.
- 15 January 2025
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
Intrathecal Baclofen Pump Wean and Risk of Exposure in a Large Total Body Surface Area Burn Wound Patient: A Case Report
Burn injuries in patients with significant preexisting medical conditions provide unique challenges in both medical management and surgical planning. Spasticity, if left untreated, can be one of the most disabling consequences of a neurologic injury. Treatment is largely dependent on pharmacologic management with antispasmodic agents such as baclofen. Baclofen’s effectiveness when taken orally is often limited by its systemic side effects, which mostly affect the CNS. Intrathecal baclofen (ITB) can circumvent these intolerable adverse effects while achieving symptom relief via a more targeted therapeutic route. However, abrupt cessation of chronic baclofen use can precipitate an acute life-threatening withdrawal syndrome. We present a case of a 47-year-old female who sustained 54% TBSA full-thickness flame burns to the circumferential bilateral lower extremities, left arm, left anterior and posterior trunk, flank, and perineum. She had a premorbid C5 spinal cord injury resulting in spastic paraplegia for which she had an ITB pump implanted into her left abdominal wall for symptom management. This pump was directly beneath her operative burn wounds. We discuss the complex issues that were encountered throughout her care related to medication reservoir supply, life-threatening risk of baclofen withdrawal, pain-specialist availability, medical-legal barriers, and the multi-staged surgical plan for coverage, balancing proper wound debridement with risk of device exposure and infection. To our knowledge, this is the only case report detailing the cohort of obstacles that may be associated with these devices, specifically with burn patients.
- 10 June 2023
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 44 (5) , 1023-1030
Evaluation of the Role of a Clinical Pharmacist on Medication Management in an Adult Burn Clinic via a Collaborative Drug Therapy Management Protocol
Historically, pharmacists have not been formally involved in managing burn clinic patients. Collaborative Drug Therapy Management (CDTM) protocols allow pharmacists working within a defined context to independently assume responsibility for direct patient care activities. The objective of this study was to evaluate the number and type of medication-related interventions made by a clinical pharmacist, in an adult burn clinic, via a CDTM protocol. The protocol allows pharmacists to independently manage the following disease states: pain, agitation, delirium, insomnia, venous thromboembolism, skin/soft tissue infections, and hypermetabolic complications. All pharmacist visits between 1/1/22 and 9/22/22 were included. A total of 16 patients were seen at 28 visits with a clinical pharmacist for a total of 148 interventions. Patients were mostly males (81%) with a mean ± SD age of 41 ± 15 years. The majority of patients were in-state (94%), with 9 (56%) being from an outlying county. Patients were seen for a median (IQR) of 2 (1,2) visits. Interventions were made at all visits (100%) with a median of 5 (4,6) per visit. Interventions (per visit) included medication reconciliation [28 (100%)], a median of 1 (0,2) medication ordered or adjusted, labs ordered at 7 (25%) visits, with adherence and patient education both reviewed at over 90% of visits. To the best of our knowledge, ours is the first burn center to implement a Clinical Pharmacist CDTM Protocol, with a pharmacist directly impacting transitions of care. This may serve as a framework for other sites. Future directions include continuing to track data for medication adherence and access, billing/reimbursement, and clinical outcomes.
- 10 June 2023
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 44 (5) , 1023-1030
Evaluation of the Role of a Clinical Pharmacist on Medication Management in an Adult Burn Clinic via a Collaborative Drug Therapy Management Protocol
Historically, pharmacists have not been formally involved in managing burn clinic patients. Collaborative Drug Therapy Management (CDTM) protocols allow pharmacists working within a defined context to independently assume responsibility for direct patient care activities. The objective of this study was to evaluate the number and type of medication-related interventions made by a clinical pharmacist, in an adult burn clinic, via a CDTM protocol. The protocol allows pharmacists to independently manage the following disease states: pain, agitation, delirium, insomnia, venous thromboembolism, skin/soft tissue infections, and hypermetabolic complications. All pharmacist visits between 1/1/22 and 9/22/22 were included. A total of 16 patients were seen at 28 visits with a clinical pharmacist for a total of 148 interventions. Patients were mostly males (81%) with a mean ± SD age of 41 ± 15 years. The majority of patients were in-state (94%), with 9 (56%) being from an outlying county. Patients were seen for a median (IQR) of 2 (1,2) visits. Interventions were made at all visits (100%) with a median of 5 (4,6) per visit. Interventions (per visit) included medication reconciliation [28 (100%)], a median of 1 (0,2) medication ordered or adjusted, labs ordered at 7 (25%) visits, with adherence and patient education both reviewed at over 90% of visits. To the best of our knowledge, ours is the first burn center to implement a Clinical Pharmacist CDTM Protocol, with a pharmacist directly impacting transitions of care. This may serve as a framework for other sites. Future directions include continuing to track data for medication adherence and access, billing/reimbursement, and clinical outcomes.
- 1 April 2021
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 42 (Supplement) , S10
6 Burn Patient Insurance Status Influences Hospital Discharge Disposition Locations
Post-discharge services, such as outpatient wound care, may affect long term health outcomes and post-recovery quality of life. Access to these services may vary according to insurance status and ability to withstand out-of-pocket expenses. Our objective was to compare discharge location between burn patients who were uninsured, publicly insured, or privately insured at the time of their burn unit admissions. We hypothesized that uninsured patients were more likely to be discharged to locations with fewer wound care resources. A retrospective review from July 1, 2015 to November 1, 2019 was performed at an ABA-verified burn center. All inpatient burn admission patients were identified and categorized according to insurance payer type. Patient and burn characteristics were recorded. The primary outcome was discharge location, and secondary outcomes included readmission and outpatient burn care attendance. In total, 284 uninsured, 565 publicly insured and 293 privately insured patients were identified. There were no significant differences in TBSA (P=0.3), presence of full thickness burn (P=0.3), inhalation injury (P=0.3), ICU days (P=0.09), ventilator days (P=0.2), or need for grafting (P=0.1). Uninsured patients were found to be younger (P< 0.0001) and more likely to be male (P=0.03). For primary outcome, uninsured patients were more likely to be discharged without ancillary services (self-care) (80.3% vs. 66.7% vs. 66.9%, P< 0.0001). Publicly insured patients were more likely to receive skilled nursing care (1.1% vs. 6.6% vs. 2.4%, P=0.0007). Privately insured patients were more likely to receive homecare (3.2% vs. 5.8% vs. 10.9%, P=0.0005) or transfer to other institutions for ongoing inpatient care (2.5% vs. 5.1% vs. 11.6%, P< 0.0001). For secondary outcomes, there was no difference in burn unit readmission (P=0.5) while uninsured were more likely to follow up in the same institution’s outpatient burn clinic after discharge (82.4% vs. 72.0% vs. 75.4%, P=0.004). Despite no differences in burn injury severity, uninsured patients were less likely to receive post-discharge resources. However, these patients were younger, which may partially explain their disproportionate discharge to self-care. Nevertheless, insured patients have greater access to non-emergent medical resources and a broader range of treatment options. Although there were no significant differences in hospital readmission, the long-term implication to differential post-discharge care is unknown. Additional studies are needed to better elucidate if discrepancies in long-term wound healing or perceived quality of life amongst these populations exist.
- 1 April 2021
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 42 (Supplement) , S10
6 Burn Patient Insurance Status Influences Hospital Discharge Disposition Locations
Post-discharge services, such as outpatient wound care, may affect long term health outcomes and post-recovery quality of life. Access to these services may vary according to insurance status and ability to withstand out-of-pocket expenses. Our objective was to compare discharge location between burn patients who were uninsured, publicly insured, or privately insured at the time of their burn unit admissions. We hypothesized that uninsured patients were more likely to be discharged to locations with fewer wound care resources. A retrospective review from July 1, 2015 to November 1, 2019 was performed at an ABA-verified burn center. All inpatient burn admission patients were identified and categorized according to insurance payer type. Patient and burn characteristics were recorded. The primary outcome was discharge location, and secondary outcomes included readmission and outpatient burn care attendance. In total, 284 uninsured, 565 publicly insured and 293 privately insured patients were identified. There were no significant differences in TBSA (P=0.3), presence of full thickness burn (P=0.3), inhalation injury (P=0.3), ICU days (P=0.09), ventilator days (P=0.2), or need for grafting (P=0.1). Uninsured patients were found to be younger (P< 0.0001) and more likely to be male (P=0.03). For primary outcome, uninsured patients were more likely to be discharged without ancillary services (self-care) (80.3% vs. 66.7% vs. 66.9%, P< 0.0001). Publicly insured patients were more likely to receive skilled nursing care (1.1% vs. 6.6% vs. 2.4%, P=0.0007). Privately insured patients were more likely to receive homecare (3.2% vs. 5.8% vs. 10.9%, P=0.0005) or transfer to other institutions for ongoing inpatient care (2.5% vs. 5.1% vs. 11.6%, P< 0.0001). For secondary outcomes, there was no difference in burn unit readmission (P=0.5) while uninsured were more likely to follow up in the same institution’s outpatient burn clinic after discharge (82.4% vs. 72.0% vs. 75.4%, P=0.004). Despite no differences in burn injury severity, uninsured patients were less likely to receive post-discharge resources. However, these patients were younger, which may partially explain their disproportionate discharge to self-care. Nevertheless, insured patients have greater access to non-emergent medical resources and a broader range of treatment options. Although there were no significant differences in hospital readmission, the long-term implication to differential post-discharge care is unknown. Additional studies are needed to better elucidate if discrepancies in long-term wound healing or perceived quality of life amongst these populations exist.